Jianxin Capital
Shanghai, China
Overview
Shanghai Jianxin equity is a Cci Capital Ltd focused on healthcare industry risk investment fund, has a professional investment team, the team has rich medical and financial investment, management and entrepreneurial experience, can make prospective investment layout according to the development trend of the industry, creating value for enterprises and investors. The company has a team of nearly 20 professional investment team, they were from medical institutions and financial class at home and abroad, with senior biomedical and financial professional background, have rich human resources in the field, the trend of development, familiar with domestic and international bio pharmaceutical industry research and development dynamics, can focus on the invested enterprise demand for product development, industrialization, management and financial investment and a full range of value-added services.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- Abbisko Therapeutics
Participated · Series A · Feb 2017
Abbisko Therapeutics is a Shanghai-based therapeutics company. The company has closed a $42-million Series B funding round. The article states the round was led by Qiming Venture Partners. No other investors are named in the article. The article does not provide details on Abbisko's products, pipeline, revenue, users, or future plans. The piece also does not disclose the intended use of proceeds or any operating metrics. Abbisko Therapeutics develops immuno-oncology drugs with a focus on small-molecule therapies targeting cancers with high incidence in Asian populations, including lung, liver, stomach and esophageal cancers. Its core pipeline comprises three preclinical compounds led by ABSK001, which is in lead optimization. The company also maintains early-stage programs in liver disease, viral infections and central nervous system disorders. Abbisko plans to use new financing to set up R&D teams and discovery centers and to advance its anticancer programs into clinical trials. The startup was set up last year and is located in the Zhangjiang biotech cluster in Shanghai. It is led by founder and CEO Yao-Chang Xu, a 25-year industry veteran with prior roles at Hansoh BioMedical, Novartis Institutes for BioMedical Research and Eli Lilly.
Team
No current team members are available.